ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zimmer Biomet Holdings, Inc. (ZBH) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks clear positive momentum, has mixed analyst sentiment, and is facing challenges in growth and profitability. While the financials show revenue growth, the significant drop in net income and EPS, along with bearish technical indicators, suggest caution. The investor should consider holding off on buying until the company's growth and profitability outlook improves.
The technical indicators for ZBH are bearish. The MACD histogram is negative (-0.683), RSI is neutral at 45.364, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 86.649, with resistance at 93.849. The stock is trading below its pivot level of 90.249, suggesting downward pressure.
Revenue increased by 10.90% YoY in Q4 2025, indicating some growth in sales. The company beat Q4 estimates amid low expectations, as noted by Citi.
Analysts have downgraded the stock, citing limited product cycles, workforce cuts, and inconsistent growth. Additionally, there are no significant hedge fund or insider trading trends to suggest confidence in the stock.
In Q4 2025, Zimmer Biomet's revenue increased to $2.24 billion (up 10.90% YoY), but net income dropped significantly to $139.3 million (-41.84% YoY). EPS decreased to $0.70 (-41.67% YoY), and gross margin fell to 56.77% (-10.19% YoY). These metrics indicate growth in sales but declining profitability.
Analyst sentiment is mixed to negative. BTIG downgraded the stock to Neutral, citing limited returns and challenges with growth and profitability. Barclays lowered the price target to $100 and maintained an Underweight rating. UBS raised the price target to $89 but kept a Sell rating. Citi raised the price target to $98 and maintained a Buy rating, while TD Cowen upgraded the stock to Buy with a $109 price target, citing potential for valuation recalibration. However, the overall sentiment reflects skepticism about the company's execution and growth prospects.
